Needham analyst has initiated coverage on Absci Corporation (NASDAQ:ABSI), a drug and target discovery company that harnesses ...

Absci's ability to generate 'wet-lab data' gives it edge, Needham analsyst says. Shares in a Vancouver-based AI drug creation company Absci soared on Wednesday after an investment firm Needham ...

Absci Corporation (ABSI) announced a strategic collaboration with AMD (AMD) to deploy AMD Instinct accelerators and ROCm software to power critical AI drug discovery workloads, including Absci’s ...

AMD’s support will enable Absci to enhance its proprietary antibody design model, IgDesign1, which is the first in vitro validated inverse folding model for antibody design.

Needham writes that Absci’s core technologies, SoluPro and ACE, are essential for a successful tech-bio company. These high-throughput platforms generate large-scale, well-documented binding ...